These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 35121553)

  • 1. Recent developments in the management of Huntington's disease.
    Devadiga SJ; Bharate SS
    Bioorg Chem; 2022 Mar; 120():105642. PubMed ID: 35121553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deutetrabenazine for tardive dyskinesia and chorea associated with Huntington's disease: a review of clinical trial data.
    Claassen DO; Philbin M; Carroll B
    Expert Opin Pharmacother; 2019 Dec; 20(18):2209-2221. PubMed ID: 31613641
    [No Abstract]   [Full Text] [Related]  

  • 3. Deutetrabenazine for the treatment of Huntington's chorea.
    Bashir H; Jankovic J
    Expert Rev Neurother; 2018 Aug; 18(8):625-631. PubMed ID: 29996061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deutetrabenazine: A Review in Chorea Associated with Huntington's Disease.
    Heo YA; Scott LJ
    Drugs; 2017 Nov; 77(17):1857-1864. PubMed ID: 29080203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. State-of-the-art pharmacological approaches to reduce chorea in Huntington's disease.
    Gibson JS; Claassen DO
    Expert Opin Pharmacother; 2021 Jun; 22(8):1015-1024. PubMed ID: 33550875
    [No Abstract]   [Full Text] [Related]  

  • 6. An experimental model for Huntington's chorea?
    Zeef DH; Jahanshahi A; Vlamings R; Casaca-Carreira J; Santegoeds RG; Janssen ML; Oosterloo M; Temel Y
    Behav Brain Res; 2014 Apr; 262():31-4. PubMed ID: 24412685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease.
    Dean M; Sung VW
    Drug Des Devel Ther; 2018; 12():313-319. PubMed ID: 29497277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Pharmacological Approaches to Reduce Chorea in Huntington's Disease.
    Coppen EM; Roos RA
    Drugs; 2017 Jan; 77(1):29-46. PubMed ID: 27988871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
    Curtis K; Sung V
    J Clin Pharmacol; 2024 Feb; 64(2):178-181. PubMed ID: 37565322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. VMAT2 inhibitors for the treatment of hyperkinetic movement disorders.
    Koch J; Shi WX; Dashtipour K
    Pharmacol Ther; 2020 Aug; 212():107580. PubMed ID: 32454050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrabenazine: for chorea associated with Huntington's disease.
    Scott LJ
    CNS Drugs; 2011 Dec; 25(12):1073-85. PubMed ID: 22133328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An MDS Evidence-Based Review on Treatments for Huntington's Disease.
    Ferreira JJ; Rodrigues FB; Duarte GS; Mestre TA; Bachoud-Levi AC; Bentivoglio AR; Burgunder JM; Cardoso F; Claassen DO; Landwehrmeyer GB; Kulisevsky J; Nirenberg MJ; Rosser A; Roth J; Seppi K; Slawek J; Furr-Stimming E; Tabrizi SJ; Walker FO; Vandenberghe W; Costa J; Sampaio C
    Mov Disord; 2022 Jan; 37(1):25-35. PubMed ID: 34842303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety of Converting From Tetrabenazine to Deutetrabenazine for the Treatment of Chorea.
    Frank S; Stamler D; Kayson E; Claassen DO; Colcher A; Davis C; Duker A; Eberly S; Elmer L; Furr-Stimming E; Gudesblatt M; Hunter C; Jankovic J; Kostyk SK; Kumar R; Loy C; Mallonee W; Oakes D; Scott BL; Sung V; Goldstein J; Vaughan C; Testa CM;
    JAMA Neurol; 2017 Aug; 74(8):977-982. PubMed ID: 28692723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrabenazine Treatment Patterns and Outcomes for Chorea Associated with Huntington Disease: A Retrospective Chart Review.
    Claassen DO; Iyer RG; Shah-Manek B; DiBonaventura M; Abler V; Sung VW
    J Huntingtons Dis; 2018; 7(4):345-353. PubMed ID: 30282372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect tolerability comparison of Deutetrabenazine and Tetrabenazine for Huntington disease.
    Claassen DO; Carroll B; De Boer LM; Wu E; Ayyagari R; Gandhi S; Stamler D
    J Clin Mov Disord; 2017; 4():3. PubMed ID: 28265459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The psychopharmacology of Huntington disease.
    Petersén Å; Weydt P
    Handb Clin Neurol; 2019; 165():179-189. PubMed ID: 31727211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington's Disease.
    Bhat SA; Ahamad S; Dar NJ; Siddique YH; Nazir A
    Curr Neuropharmacol; 2023; 21(4):867-889. PubMed ID: 36797612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physician perceptions of pharmacologic treatment options for chorea associated with Huntington disease in the United States.
    Sung VW; Iyer RG; Gandhi SK; Shah-Manek B; DiBonaventura M; Abler V; Claassen DO
    Curr Med Res Opin; 2018 Apr; 34(4):643-648. PubMed ID: 29383957
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine.
    Setter SM; Neumiller JJ; Dobbins EK; Wood L; Clark J; DuVall CA; Santiago A
    Consult Pharm; 2009 Jul; 24(7):524-37. PubMed ID: 19689181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the treatment studies in Huntington's disease since 1990.
    Bonelli RM; Hofmann P
    Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.